Blogs

A recent study by researchers at Mount Sinai School of Medicine published in the journal (PLoS) One, from the Public Library of Science found that most pharmaceutical advertisements in biomedical journals fail to comply with US Food and Drug Administration (FDA) guidelines. The researchers looked at 192 ads and judged that only 18% were FDA-compliant. More than half (57.8%) failed to quantify serious risks such as death, according to the report. The findings may have implications for FDA’s "Bad Ad" program. "The limited resources of the FDA's Division of Drug Marketing and Advertising are a major barrier to successful regulation of the pharmaceutical industry's multi-billion dollar marketing budget," said Dr. Deborah Korenstein, the study’s lead author.

Read more:

• Majority of pharma journal ads not FDA-compliant: study (Medical Marketing & Media)
• Majority of Pharmaceutical Ads Do Not Adhere to FDA Guidelines, New Study Finds (Science Daily)
• Take those medical journal pharmaceutical ads with grain of salt (Los Angeles Times)
• Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing (PLoS One)
• Majority of Pharmaceutical Ads Do Not Adhere to FDA Guidelines  (Mount Sinai Medical Center press release)